FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224867665> ?p ?o ?g. }

• W4224867665 endingPage "1484" @default.
• W4224867665 startingPage "1473" @default.
• W4224867665 abstract "Diltiazem is recommended and frequently prescribed in patients with angina and nonobstructive coronary artery disease (ANOCA), suspected of coronary vasomotor dysfunction (CVDys). However, studies substantiating its effect is this patient group are lacking.The randomized, placebo-controlled EDIT-CMD (Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: A Randomized Clinical Trial) evaluated the effect of diltiazem on CVDys, as assessed by repeated coronary function testing (CFT), angina, and quality of life.A total of 126 patients with ANOCA were included and underwent CFT. CVDys, defined as the presence of vasospasm (after intracoronary acetylcholine provocation) and/or microvascular dysfunction (coronary flow reserve: <2.0, index of microvascular resistance: ≥25), was confirmed in 99 patients, of whom 85 were randomized to receive either oral diltiazem or placebo up to 360 mg/d. After 6 weeks, a second CFT was performed. The primary end point was the proportion of patients having a successful treatment, defined as normalization of 1 abnormal parameter of CVDys and no normal parameter becoming abnormal. Secondary end points were changes from baseline to 6-week follow-up in vasospasm, index of microvascular resistance, coronary flow reserve, symptoms (Seattle Angina Questionnaire), or quality of life (Research and Development Questionnaire 36).In total, 73 patients (38 diltiazem vs 35 placebo) underwent the second CFT. Improvement of the CFT did not differ between the groups (diltiazem vs placebo: 21% vs 29%; P = 0.46). However, more patients on diltiazem treatment progressed from epicardial spasm to microvascular or no spasm (47% vs 6%; P = 0.006). No significant differences were observed between the diltiazem and placebo group in microvascular dysfunction, Seattle Angina Questionnaire, or Research and Development Questionnaire 36.This first performed randomized, placebo-controlled trial in patients with ANOCA showed that 6 weeks of therapy with diltiazem, when compared with placebo, did not substantially improve CVDys, symptoms, or quality of life, but diltiazem therapy did reduce prevalence of epicardial spasm. (Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: A Randomized Clinical Trial [EDIT-CMD]; NCT04777045)." @default.
• W4224867665 created "2022-04-27" @default.
• W4224867665 creator A5028664282 @default.
• W4224867665 creator A5042053355 @default.
• W4224867665 creator A5052077785 @default.
• W4224867665 creator A5053893959 @default.
• W4224867665 creator A5053970820 @default.
• W4224867665 creator A5058243148 @default.
• W4224867665 creator A5060914289 @default.
• W4224867665 creator A5069357648 @default.
• W4224867665 creator A5078178464 @default.
• W4224867665 creator A5089037313 @default.
• W4224867665 creator A5091436608 @default.
• W4224867665 creator A5091757416 @default.
• W4224867665 date "2022-08-01" @default.
• W4224867665 modified "2023-10-11" @default.
• W4224867665 title "Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA" @default.
• W4224867665 cites W1968602190 @default.
• W4224867665 cites W1978584044 @default.
• W4224867665 cites W1984880976 @default.
• W4224867665 cites W2030973682 @default.
• W4224867665 cites W2078833361 @default.
• W4224867665 cites W2104695445 @default.
• W4224867665 cites W2112627685 @default.
• W4224867665 cites W2115841204 @default.
• W4224867665 cites W2120724015 @default.
• W4224867665 cites W2135415614 @default.
• W4224867665 cites W2149755434 @default.
• W4224867665 cites W2156024415 @default.
• W4224867665 cites W2394828260 @default.
• W4224867665 cites W2799318490 @default.
• W4224867665 cites W2800800661 @default.
• W4224867665 cites W2893412710 @default.
• W4224867665 cites W2939337927 @default.
• W4224867665 cites W2983435500 @default.
• W4224867665 cites W2983517593 @default.
• W4224867665 cites W3011371150 @default.
• W4224867665 cites W3014622906 @default.
• W4224867665 cites W3039582598 @default.
• W4224867665 cites W3086940917 @default.
• W4224867665 cites W3094839338 @default.
• W4224867665 cites W3126686642 @default.
• W4224867665 cites W3128977419 @default.
• W4224867665 cites W3134682297 @default.
• W4224867665 cites W4205135062 @default.
• W4224867665 cites W4235146414 @default.
• W4224867665 cites W4382891181 @default.
• W4224867665 doi "https://doi.org/10.1016/j.jcmg.2022.03.012" @default.
• W4224867665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35466050" @default.
• W4224867665 hasPublicationYear "2022" @default.
• W4224867665 type Work @default.
• W4224867665 citedByCount "29" @default.
• W4224867665 countsByYear W42248676652022 @default.
• W4224867665 countsByYear W42248676652023 @default.
• W4224867665 crossrefType "journal-article" @default.
• W4224867665 hasAuthorship W4224867665A5028664282 @default.
• W4224867665 hasAuthorship W4224867665A5042053355 @default.
• W4224867665 hasAuthorship W4224867665A5052077785 @default.
• W4224867665 hasAuthorship W4224867665A5053893959 @default.
• W4224867665 hasAuthorship W4224867665A5053970820 @default.
• W4224867665 hasAuthorship W4224867665A5058243148 @default.
• W4224867665 hasAuthorship W4224867665A5060914289 @default.
• W4224867665 hasAuthorship W4224867665A5069357648 @default.
• W4224867665 hasAuthorship W4224867665A5078178464 @default.
• W4224867665 hasAuthorship W4224867665A5089037313 @default.
• W4224867665 hasAuthorship W4224867665A5091436608 @default.
• W4224867665 hasAuthorship W4224867665A5091757416 @default.
• W4224867665 hasBestOaLocation W42248676651 @default.
• W4224867665 hasConcept C126322002 @default.
• W4224867665 hasConcept C142724271 @default.
• W4224867665 hasConcept C164705383 @default.
• W4224867665 hasConcept C168563851 @default.
• W4224867665 hasConcept C204787440 @default.
• W4224867665 hasConcept C27081682 @default.
• W4224867665 hasConcept C2776741139 @default.
• W4224867665 hasConcept C2778213512 @default.
• W4224867665 hasConcept C2778425758 @default.
• W4224867665 hasConcept C42219234 @default.
• W4224867665 hasConcept C500558357 @default.
• W4224867665 hasConcept C519063684 @default.
• W4224867665 hasConcept C71924100 @default.
• W4224867665 hasConceptScore W4224867665C126322002 @default.
• W4224867665 hasConceptScore W4224867665C142724271 @default.
• W4224867665 hasConceptScore W4224867665C164705383 @default.
• W4224867665 hasConceptScore W4224867665C168563851 @default.
• W4224867665 hasConceptScore W4224867665C204787440 @default.
• W4224867665 hasConceptScore W4224867665C27081682 @default.
• W4224867665 hasConceptScore W4224867665C2776741139 @default.
• W4224867665 hasConceptScore W4224867665C2778213512 @default.
• W4224867665 hasConceptScore W4224867665C2778425758 @default.
• W4224867665 hasConceptScore W4224867665C42219234 @default.
• W4224867665 hasConceptScore W4224867665C500558357 @default.
• W4224867665 hasConceptScore W4224867665C519063684 @default.
• W4224867665 hasConceptScore W4224867665C71924100 @default.
• W4224867665 hasFunder F4320306493 @default.
• W4224867665 hasFunder F4320307766 @default.
• W4224867665 hasFunder F4320333259 @default.
• W4224867665 hasIssue "8" @default.

• next